Findings from the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial indicate that the strongest predictors of prostate cancer-specific mortality include Gleason 7, body mass index >30, African-American race, PSA level, stage, and high co-morbidity score. Understanding how non-tumor factors affect prostate cancer-specific mortality will help identify those men who may benefit from screening and treatment.
By Malecare|2010-07-14T14:41:43-04:00July 14th, 2010|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Uncategorized, Understanding APC|0 Comments
About the Author: Malecare
Malecare is the world's leading men's cancer support and advocacy nonprofit organization.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Leave A Comment